论文信息 - Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. - 字舞流文

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

J. Carles | Choung-Soo Kim | A. Font | M. Eisenberger | J. D. de Bono | P. Parente | L. Geczi | A. Hardy-Bessard | G. Kacso | M. Chadjaa | L. Mourey | D. Ford | J. Bernard | Wenping Zhang | L. Géczi